My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

1.400 +0.180 (+14.75%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

March 03, 2025

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

February 27, 2025

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 05, 2025

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

December 02, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts ↗

August 19, 2024

Via Benzinga

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

November 12, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics to Host Investor Event

October 31, 2024

KCC2 Download Day on Wednesday, November 13, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 16, 2024

Via Benzinga

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

September 26, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

The Latest Analyst Ratings For Ovid Therapeutics ↗

July 26, 2024

Via Benzinga

Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts ↗

June 18, 2024

Via Benzinga

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

September 11, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics to Present at Upcoming September Investor Conferences

September 04, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 13, 2024

OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

August 13, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

August 08, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

August 01, 2024

From The Schall Law Firm

Via Business Wire

Ovid Therapeutics to Present at Upcoming August Investor Conferences

July 30, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

July 23, 2024

Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain

From Ovid Therapeutics Inc.

Via GlobeNewswire

7 Sorry Biotech Stocks Set to Make Investors Sad ↗

July 22, 2024

Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.

Via InvestorPlace

eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

July 10, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

July 01, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Nasdaq Surges Over 200 Points; Aaron's Shares Jump ↗

June 17, 2024

Via Benzinga

Is the Stock Market Closed on Juneteenth 2024? ↗

June 17, 2024

Investors wondering if the stock market is closed on Juneteenth 2024 have come to the right place as we have an answer to that question!

Via InvestorPlace

ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation ↗

June 17, 2024

Archer Aviation stock is down on Monday after the company alerted ACHR investors to a new MOU signed with Signature Aviation.

Via InvestorPlace

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 17, 2024

Via Benzinga

AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal ↗

June 17, 2024

The Aaron's Company stock is up on Monday after it announced a take-private deal that values AAN shares at $10.10 each.

Via InvestorPlace

Why Is Ovid Therapeutics (OVID) Stock Down 69% Today? ↗

June 17, 2024

Ovid Therapeutics stock is down on Monday with heavy trading of OVID shares after the company reported a failed Phase3 clinical trial.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 17, 2024

Via Benzinga

Crude Oil Rises 1%; Mustang Bio Shares Spike Higher ↗

June 17, 2024

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.